Table 3 |
|||
|
Multivariate analysis of MRSA versus MSSA: duration of MV, inpatient LOS, ICU LOS, and total cost |
|||
|
Dependent variables |
MRSA estimate (95% CI) |
P value |
Model r2 |
|
|
|||
|
Total MV (days) |
4.4 (0.6 to 8.2) |
0.03 |
0.16 |
|
VAP MV (days) |
4.5 (1.0 to 8.1) |
0.01 |
0.10 |
|
Total inpatient LOS (days) |
3.8 (-0.5 to +8.0) |
0.08 |
0.26 |
|
VAP inpatient LOS (days) |
3.7 (-0.5 to +8.0) |
0.08 |
0.06 |
|
Total ICU (days)a |
5.3 (1.0 to 9.7) |
0.02 |
0.13 |
|
VAP ICU (days)a |
4.4 (0.4 to 8.4) |
0.03 |
0.10 |
|
Total cost (US$) |
7731 (-8393 to +23,856) |
0.35 |
0.28 |
|
|
|||
|
A total of 154 patients were included in this analysis. aAnalysis for ICU days was conducted on patients (n = 95) from hospitals that collect ICU stay data. CI, confidence interval; ICU, intensive care unit; LOS, length of stay; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; MV, mechanical ventilation; VAP, ventilator-associated pneumonia. |
|||
|
Shorr et al. Critical Care 2006 10:R97 doi:10.1186/cc4934 |
|||
